The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment

Oncologist

Volumn 18, Issue 1, 2013, Pages 27-36

  Garrison, Louis P ^a   Wang, Si Tien ^b   Huang, Hui ^c   Ba Mancini, Abbie ^c   Shi, Hongliang ^c   Chen, Kristina ^b   Korves, Caroline ^b   Dhawan, Ravinder ^d   Cakana, Andrew ^e   van de Velde, Helgi ^e   Corzo, Deyanira ^c   Duh, Mei Sheng ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ANALYSIS GROUP   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Bortezomib; Cost effectiveness; Lenalidomide; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ANEMIA; ARTICLE; ASTHENIA; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG DOSE INCREASE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INFECTION; KIDNEY FAILURE; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SENSITIVITY ANALYSIS; THROMBOCYTOPENIA;

EID: 84873047409     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0380     Document Type: Article

References (30)

1. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiplemyelomaandthe impact of novel therapies. Blood 2008; 111: 2516-2520.
2. Laubach JP, Mitsiades CS, Mahindra A et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009; 7: 947-960.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Cancer. Multiple Myeloma, Version 1. 2012. National Comprehensive Cancer Network, Fort Washington, PA. 2012: 1-59.
4. Engelhardt M, Kleber M, Udi J et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: From standard therapy to novel approaches. Leuk Lymphoma 2010; 51: 1424-1443.
5. Beksac M, Haznedar R, Firatli-Tuglular T et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: Results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 2011; 86: 16-22.
6. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiplemyeloma (IFM99-06): Arandomised trial. Lancet 2007; 370: 1209-1218.
7. Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27: 3664-3670.
8. Mateos MV, Richardson PG, Schlag R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28: 2259-2266.
9. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367: 825-831.
10. Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial. Blood 2008; 112: 3107-3114.
11. Palumbo A, Dimopoulos MA, Delforge M et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma [oral presentation]. Blood 2009; 114: 613.
12. Palumbo A, Dimopoulos M, Delforge M et al. A phase 3 study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients >65 years with newly diagnosed multiple myeloma (NDMM) [abstract 0566]. Haematologica 2010; 95 (suppl 2): 234.
13. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
14. Waage A, Gimsing P, Fayers P et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010; 116: 1405-1412.
15. Wijermans P, Schaafsma M, Termorshuizen F et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol 2010; 28: 3160-3166.
16. Ludwig H, Beksac M, Bladé J et al. Multiple myeloma treatment strategies with novel agents in 2011: A European perspective. The Oncologist 2011; 16: 388-403.
17. San Miguel JF, Schlag R, Khuageva NK et al. Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: Final results of the phase 3 VISTA trial. Blood 2011; 118: 476.
18. Waage A, Palumbo AP, Fayers P et al. MP versus MPT for previously untreated elderly patients with multiplemyeloma: Ameta-analysis of 1, 682 individual patient data from six randomized clinical trials. J Clin Oncol 2010; 28: 8130.
19. Kapoor P, Rajkumar SV, Dispenzieri A et al. Melphalanandprednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: A meta-analysis. Leukemia 2011; 25: 689-696.
20. Palumbo A, Delforge M, Catalano J et al. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients >65 years with newly diagnosed multiple myeloma (NDMM): Continuous use of lenalidomide vs fixed-duration regimens. Blood 2010; 116: 622.
21. Philips Z, Ginnelly L, Sculpher M et al. Reviewof guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8: iii-iv, ix-xi, 1-158.
22. Brock DW. Howmuchismorelife worth? Hastings Cent Rep 2006; 36: 17-19.
23. Elkin EB, Weinstein MC, Winer EP et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2004; 22: 854-863.
24. Millennium Pharmaceuticals, Inc. Velcade® (bortezomib) for injection [prescribing information], Revision 13, January 2012.
25. Picot J, Cooper K, Bryant J et al. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the firstline treatment of multiple myeloma: A systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-204.
26. Hornberger J, Rickert J, Dhawan R et al. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. Eur J Haematol 2010; 85: 484-491.
27. Bagust A, Haycox AR, Boland A et al. Economic evaluation of bortezomib (Velcade) for relapsed and refractory multiple myeloma. Blood 2004; 104: 268.
28. Deniz B, Morgan G, Schey S et al. Economic evaluation of lenalidomide combined with dexamethasone for the treatment of multiple myeloma in the UK. Blood 2008; 112: 2400.
29. Deniz B, Facon T, Singer I et al. Economic evaluation of thalidomide combined with melphalan and prednisone in previously untreated multiple myeloma in Scotland. Blood 2008; 112: 2395.
30. Mehta J, Duff SB, Gupta S. Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma. Manag Care Interface 2004; 17: 52-61.